Page 42 - 《中国药房》2025年18期
P. 42

表没食子儿茶素没食子酸酯提高肝癌细胞对仑伐替尼敏感性的

          机制     Δ



          宋传芳 ,艾 江,温 超,张 杰,崔江河(牡丹江医科大学附属红旗医院消化内科,黑龙江 牡丹江 157011)
                                                #
                *
          中图分类号  R965      文献标志码  A      文章编号  1001-0408(2025)18-2256-06
          DOI  10.6039/j.issn.1001-0408.2025.18.07

          摘   要  目的  基于磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(Akt)信号通路探讨表没食子儿茶素没食子酸酯(EGCG)提高肝癌细胞
          对仑伐替尼敏感性的潜在机制。方法  以HepG2、Huh-7、SMMC-7721、SNU-368、SNU-739 5种人肝癌细胞为对象,探讨仑伐替尼、
          EGCG+仑伐替尼对细胞存活率、克隆形成数、增殖率、侵袭数和通路相关mRNA及蛋白表达的影响;引入PI3K激动剂[胰岛素样
          生长因子1(IGF-1)],考察激活PI3K/Akt信号通路对EGCG增敏作用的影响。结果  与对照组比较,仑伐替尼组(10 μmol/L)、不同
          质量浓度EGCG+仑伐替尼组(1、5、10 μg/mL EGCG+10 μmol/L仑伐替尼)5种肝癌细胞的存活率和克隆形成数均呈浓度依赖性降
          低(P<0.05);仑伐替尼组(10 μmol/L)、EGCG+仑伐替尼组(10 μg/mL EGCG+10 μmol/L仑伐替尼)5种肝癌细胞的增殖率和侵袭
          数,HepG2细胞或5种细胞中PI3K、Akt、哺乳动物雷帕霉素靶蛋白(mTOR)、P70S6K、4EBP mRNA的表达以及PI3K、Akt蛋白的磷
          酸化水平和 mTOR、B 细胞淋巴瘤 2(Bcl-2)蛋白的表达均显著降低或下调,而第 10 号染色体缺失的磷酸酶及张力蛋白同源物
         (PTEN)mRNA及蛋白、胱天蛋白酶3(caspase-3)、剪切的胱天蛋白酶3(cleaved caspase-3)的表达均显著上调(P<0.05);且EGCG+
          仑伐替尼组上述指标的变化较仑伐替尼组更为显著(P<0.05)。与仑伐替尼组、EGCG+仑伐替尼组比较,EGCG+仑伐替尼+IGF-1
          组(10 μg/mL EGCG+10 μmol/L 仑伐替尼+50 ng/mL IGF-1)HepG2 细胞的克隆形成数、增殖率及侵袭数均显著升高(P<0.05)。
          结论  EGCG可增加肝癌细胞对仑伐替尼的敏感性,其作用机制可能与抑制PI3K/Akt信号通路激活有关。
          关键词  表没食子儿茶素没食子酸酯;肝癌;仑伐替尼;增敏作用;PI3K/Akt信号通路

          The  mechanism  of  epigallocatechin  gallate  enhancing  the  sensitivity  of  hepatocellular  carcinoma  cells  to
          lenvatinib
          SONG Chuanfang,AI Jiang,WEN Chao,ZHANG Jie,CUI Jianghe(Dept. of Gastroenterology, Hongqi Hospital
          Affiliated to Mudanjiang Medical University, Heilongjiang Mudanjiang 157011, China)

          ABSTRACT    OBJECTIVE  To  investigate  the  potential  mechanism  of  epigallocatechin  gallate (EGCG)  enhancing  the  sensitivity
          of  hepatocellular  carcinoma (HCC)  cells  to  lenvatinib  based  on  the  phosphoinositide  3-kinase (PI3K)/protein  kinase  B (Akt)
          signaling pathway. METHODS Five human HCC cell lines (HepG2, Huh-7, SMMC-7721, SNU-368 and SNU-739) were used to
          evaluate the effects of lenvatinib alone and in combination with EGCG on survival rates, clone number, proliferation rate, invasion
          number  and  the  expressions  of  mRNAs  and  proteins  related  to  the  PI3K/Akt  signaling  pathway.  The  PI3K  activator  insulin-like
          growth  factor-1 (IGF-1)  was  introduced  to  investigate  the  effect  of  activating  the  PI3K/Akt  signaling  pathway  on  the  sensitization
          effect  of  EGCG.  RESULTS  Compared  with  the  control  group,  lenvatinib (10  μmol/L)  and  different  concentrations  of  EGCG+
          lenvatinib (1, 5 and 10 μg/mL EGCG+10 μmol/L lenvatinib) significantly reduced the survival rates and clone numbers of all five
          HCC cell lines in a dose-dependent manner (P<0.05). Lenvatinib (10 μmol/L) and EGCG+lenvatinib (10 μg/mL EGCG+10 μmol/L
          lenvatinib) also markedly inhibited the proliferation rate and invasion numbers of these cells, and decreased the mRNA expressions
          of PI3K, Akt, mammalian target of rapamycin (mTOR), P70S6K and 4EBP, and the phosphorylation levels of PI3K and Akt, as
          well  as  the  protein  expressions  of  mTOR  and  B  cell  lymphoma-2 (Bcl-2)  in  HepG2  cells  or  all  five  HCC  cells;  conversely,  the
          mRNA  and  protein  expressions  of  phosphatase  and  tensin  homologue  deleted  on  chromosome  10(PTEN),  and  the  protein
          expressions  of  caspase-3  and  cleaved  caspase-3  were  significantly  upregulated,  with  more  pronounced  effects  observed  in  the
          EGCG+lenvatinib  group  than  in  the  lenvatinib  group (P<0.05).  Compared  with  the  lenvatinib  group  and  the  EGCG+lenvatinib
          group, the clone number, proliferation rate and invasion number of HepG2 cells in the EGCG+lenvatinib+IGF-1 group (10 μg/mL
          EGCG+10  μmol/L  lenvatinib+50  ng/mL  IGF-1)  were  significantly  increased (P<0.05).  CONCLUSIONS  EGCG  can  enhance  the
          sensitivity of HCC cells to lenvatinib, and its underlying mechanism may be related to the inhibition of the activation of PI3K/Akt
                                                              signaling pathway activation.
              Δ 基金项目 黑龙江省自然科学基金项目(No.2023JJ0008)              KEYWORDS    epigallocatechin  gallate;  hepatocellular  car-
             *第一作者 主治医师,硕士。研究方向:消化系统肿瘤。E-mail:
                                                              cinoma;  lenvatinib;  sensitization  effect;  PI3K/Akt  signaling
          songchuanfang1988@163.com
                                                              pathway
              # 通信作者 副主任医师。研究方向:消化系统肿瘤。E-mail:
          18215039@qq.com


          · 2256 ·    China Pharmacy  2025 Vol. 36  No. 18                            中国药房  2025年第36卷第18期
   37   38   39   40   41   42   43   44   45   46   47